Original Report

End-of-life home care utilization and costs in patients with advanced colorectal cancer


 

Bacground Colorectal cancer is one of the leading causes of morbidity and mortality in Canada. A report of community dwelling seniors showed that 25% received some sort of home care, and that the quantity of home care increased with age and disability. Few population-based studies have examined home care and the associated costs in elderly persons with cancer.

Objective To determine overall utilization and costs associated with home care services in Ontario, Canada by linking a home care database to a stage IV colorectal cancer cohort.

Methods The names of patients with stage IV colorectal cancer at time of diagnosis (diagnosed from 2005 through 2009) were extracted from the Ontario Cancer Registry. The study cohort comprised those who died before the end of the study. The terminal phase of care was the period of time between diagnosis and death, with a maximum value of 180 days (6 months). Patients were linked to home care services datasets. The type, frequency, and cost of home care services were determined. Regression analysis was used to examine factors associated with utilization and cost.

Results In all, 3,613 stage IV colorectal cancer patients (median age, 71 years) were diagnosed and died during the study’s time horizon. During the terminal phase, 79.3% received at least 1 home care visit, and 58.0% had at least 1 palliative visit. Terminal metastatic colorectal cancer patients received an average of 8 home care visits at Canadian $800 within a 30-day time horizon. Home care costs were highest in the month before death. Male sex, a history of moderate or high utilization of health care services, and hospitalization were associated with lower home care costs.

Limitations Administrative data do not reveal the purpose, efficiency, effectiveness/sufficiency, quality, or appropriateness of home care.

Conclusion Patients with advanced colorectal cancer who were approaching death required a moderate level of home care support, resulting in costs of about $5,000 over the 6-month time horizon.

Funding This study was conducted with the support of the Ontario Institute for Cancer Research and Cancer Care Ontario through funding provided by the government of Ontario. Data were provided by Cancer Care Ontario and the Institute for Clinical Evaluative Sciences. The ICES also provided funding for the study from an annual grant by the Ontario Ministry of Health and Long-term Care.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Interval CRC may be distinct pathology
MDedge Hematology and Oncology
Surgical complications no higher for rectal cancer patients with IBD
MDedge Hematology and Oncology
Patient selection can keep the lid on esophagectomy costs
MDedge Hematology and Oncology
FDA panel says blood test for colorectal cancer screening is safe, not effective
MDedge Hematology and Oncology
FDA panel unanimously supports Cologuard colorectal cancer test
MDedge Hematology and Oncology
Better survival with aspirin in HLA class 1 antigen-positive cancers only
MDedge Hematology and Oncology
Physician’s adenoma detection rate predicts patient’s cancer risk
MDedge Hematology and Oncology
Induction therapy does not complicate minimally invasive esophagectomy
MDedge Hematology and Oncology
Few eligible patients undergo radical cholecystectomy
MDedge Hematology and Oncology
Angiogenesis inhibitor approved for advanced gastric cancer
MDedge Hematology and Oncology